WebApr 11, 2024 · Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA. Read More BPMC Stock News Headlines WebJan 23, 2024 · CAMBRIDGE, Mass., Jan. 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...
Blueprint Medicines Annual Report 2024 - StockLight
WebBlueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets. Cambridge, Massachusetts, United States 251-500 Post-IPO Equity … WebApr 8, 2024 · About Blueprint Medicines' Clinical Development Programs in EGFR-Mutant NSCLC. Blueprint Medicines is developing three investigational agents, BLU-701, BLU-945 and BLU-451, with the goal of addressing nearly all activating mutations (>90 percent) in EGFR-mutant NSCLC. The introduction of EGFR-targeted therapies, including … pogacha seattle
Annual Report (10-k)
WebJan 20, 2024 · Dr. Lee joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team. During her tenure, she has been instrumental in building the company's … WebBLUEPRINT MEDICINES CORPORATION (Exact name of registrant as specified in its charter) Delaware 26-3632015 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 45 Sidney Street Cambridge, MA 02139 (Address of principal executive offices) (Zip Code) WebSr. Manager, Learning & Development at Blueprint Medicines Atlanta Metropolitan Area. 1K followers 500+ connections. Join to view profile … pogachas in bellevue